Alkermes Reports Q1 2026 Earnings with Strong Sales Growth and Increased Expenses
Alkermes (ALKS) reported Q1 2026 earnings with a 38% year-over-year increase in proprietary product net sales, driven by demand in psychiatry and addiction. However, the company faced increased SGA and R&D expenses, and revised its tax guidance downward. The company also discussed potential generic competition for VIVITROL in 2027.
Topics: Earnings Market Competition Product Launch R&D Expenses Sales Performance Tax Guidance